A decision-analytic approach to define poor prognosis patients: A case study for non-seminomatous germ cell cancer patients

BMC Medical Informatics and Decision Making

Volumn 8, Issue , 2008, Pages

  Van Dijk, Merel R ^a   Steyerberg, Ewout W ^a   Habbema, J Dik F ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CLASSIFICATION; CANCER PATIENT; CANCER RISK; DECISION MAKING; DRUG MEGADOSE; GERM CELL TUMOR; MORTALITY; SEMINOMA; ADOLESCENT; ADULT; DECISION SUPPORT SYSTEM; HUMAN; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASM; PROGNOSIS; STEM CELL TRANSPLANTATION; TESTIS TUMOR;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DECISION SUPPORT TECHNIQUES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; PROGNOSIS; STEM CELL TRANSPLANTATION; TESTICULAR NEOPLASMS;

EID: 41649095948     PISSN: None     EISSN: 14726947     Source Type: Journal    
DOI: 10.1186/1472-6947-8-1     Document Type: Article

References (41)

1. Prognostic importance of comorbidity in a hospital-based cancer registry. JF Piccirillo RM Tierney I Costas L Grove EL Spitznagel Jr., Jama 2004 291 20 2441 2447 10.1001/jama.291.20.2441 15161894
2. Statistical aspects of prognostic factor studies in oncology. R Simon DG Altman, Br J Cancer 1994 69 6 979 985 8198989
3. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. FE Harrell Jr. KL Lee DB Mark, Stat Med 1996 15 4 361 387 10.1002/(SICI)1097-0258(19960229)15: 4<361::AID-SIM168〉3.0.CO;2-4 8668867
4. An evidence based approach to individualising treatment. PP Glasziou LM Irwig, Bmj 1995 311 7016 1356 1359 7496291
5. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: An extended phase I/II study of the German testicular cancer study group. HJ Schmoll C Kollmannsberger B Metzner JT Hartmann N Schleucher P Schoffski J Schleicher O Rick J Beyer D Hossfeld L Kanz WE Berdel R Andreesen C Bokemeyer, J Clin Oncol 2003 21 22 4083 4091 10.1200/JCO.2003.09.035 14568987
6. First-line high-dose chemotherapy for 'poor risk' metastatic non-seminomatous testicular germ cell tumors. C Bokemeyer A Harstrick J Beyer B Metzner U Ruther JT Hartmann K Holstein HG Derigs R de Wit J Casper P Schoffski I Kuhrer HJ Illiger B Kempf A Reichle A Foller DK Hossfeld JT Fischer W Berdel H Gerhartz H Kirchner K Pfluger H Ostermann L Kanz HJ Schmoll, Onkologie 1998 21 23 25 10.1159/000054966
7. Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer. C Bokemeyer K Oechsle JT Hartmann P Schoffski N Schleucher B Metzner J Schleicher L Kanz, Br J Cancer 2002 87 10 1066 1071 10.1038/sj.bjc.6600629 12402143
8. Phase III Randomized Study of Standard Cisplatin, Etoposide, and Ifosfamide (VIP) Followed By Sequential High-Dose VIP and Stem Cell Rescue Versus Bleomycin, Etoposide, and Cisplatin (BEP) in Chemotherapy-Naive Men With Poor-Prognosis Germ Cell Cancer. EORTC, http://www.cancer.gov/search/ ViewClinicalTrials.aspx?cdrid=67134&version=HealthProfessional& protocolsearchid=1480362
9. Phase III Randomized Study of Bleomycin, Etoposide, and Cisplatin (BEP) With or Without High-Dose Carboplatin, Etoposide, and Cyclophosphamide Plus Autologous Bone Marrow or Peripheral Blood Stem Cell Transplantation in Male Patients With Previously Untreated Poor- or Intermediate-Risk Germ Cell Tumors. USiintergroup, 2006
10. Long-term complications of chemotherapy for germ cell tumours. UB Chaudhary JR Haldas, Drugs 2003 63 15 1565 1577 10.2165/00003495-200363150-00004 12887263
11. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. IGCCCG, J Clin Oncol 1997 15 2 594 603 9053482
12. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. R de Wit JT Roberts PM Wilkinson PH de Mulder GM Mead SD Fossa P Cook L de Prijck S Stenning L Collette, J Clin Oncol 2001 19 6 1629 1640 11250991
13. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial. S Hinton PJ Catalano LH Einhorn CR Nichols E David Crawford N Vogelzang D Trump PJ Loehrer Sr., Cancer 2003 97 8 1869 1875 10.1002/cncr.11271 12673712
14. The changing distribution of stage in nonseminomatous testicular germ cell tumours, from 1977 to 1996. DJ Sonneveld HJ Hoekstra WT Van Der Graaf WJ Sluiter H Schraffordt Koops DT Sleijfer, BJU Int 1999 84 1 68 74 10.1046/j.1464-410x.1999.00072.x 10444127
15. Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: An update based on meta-analysis. MR van Dijk EW Steyerberg JD Habbema, Eur J Cancer 2006 42 7 820 826 10.1016/j.ejca.2005.08.043 16574403
16. One thousand health-related quality-of-life estimates. TO Tengs A Wallace, Med Care 2000 38 6 583 637 10.1097/00005650-200006000-00004 10843310
17. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era. DJA Sonneveld HJ Hoekstra WT van der Graaf WJ Sluiter NH Mulder PHB Willemse HS Koops DT Sleijfer, Cancer 2001 91 7 1304 1315 10.1002/1097-0142(20010401)91:7<1304::AID-CNCR1133〉3.0.CO;2-A 11283931
18. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. C Bokemeyer C Kollmannsberger C Meisner A Harstrick J Beyer B Metzner JT Hartmann HJ Schmoll L Einhorn L Kanz C Nichols, J Clin Oncol 1999 17 11 3450 3456 10550141
19. Testicular germ-cell cancer. GJ Bosl RJ Motzer, N Engl J Med 1997 337 4 242 253 10.1056/NEJM199707243370406 9227931
20. High-dose chemotherapy for solid tumors: results of the EBMT. G Rosti P Ferrante J Ledermann S Leyvraz R Ladenstein E Koscileniak J Crown C Dazzi A Cariello M Marangolo, Crit Rev Oncol Hematol 2002 41 2 129 140 10.1016/S1040-8428(01)00150-0 11856589
21. Evaluation of long-term toxicity after chemotherapy for testicular cancer. C Bokemeyer CC Berger MA Kuczyk HJ Schmoll, J Clin Oncol 1996 14 11 2923 2932 8918489
22. Therapy-related malignancies following treatment of germ cell cancer. C Kollmannsberger JT Hartmann L Kanz C Bokemeyer, Int J Cancer 1999 83 6 860 863 10.1002/(SICI)1097-0215(19991210)83:6<860::AID-IJC32〉3.0.CO;2-L 10597212
23. Trends in leukemia incidence and survival in the United States (1973-1998). Y Xie SM Davies Y Xiang LL Robison JA Ross, Cancer 2003 97 9 2229 2235 10.1002/cncr.11316 12712476
24. Cardiovascular disease as a long-term complication of treatment for testicular cancer. RA Huddart A Norman M Shahidi A Horwich D Coward J Nicholls DP Dearnaley, J Clin Oncol 2003 21 8 1513 1523 10.1200/JCO.2003.04.173 12697875
25. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. MT Meinardi JA Gietema WT van der Graaf DJ van Veldhuisen MA Runne WJ Sluiter EG de Vries PB Willemse NH Mulder MP van den Berg HS Koops DT Sleijfer, J Clin Oncol 2000 18 8 1725 1732 10764433
26. Sexual functioning after treatment for testicular cancer - review and meta-analysis of 36 empirical studies between 1975-2000. G Jonker-Pool HB Van de Wiel HJ Hoekstra DT Sleijfer MF Van Driel JP Van Basten HS Schraffordt Koops, Arch Sex Behav 2001 30 1 55 74 10.1023/A:1026468707362 11286005
27. Short- and long-term effects of acute myeloid leukemia on patient health-related quality of life. A Redaelli JM Stephens S Brandt MF Botteman CL Pashos, Cancer Treat Rev 2004 30 1 103 117 10.1016/S0305-7372(03)00142-7 14766128
28. Selecting patients for randomized trials: a systematic approach based on risk group. AJ Vickers BS Kramer SG Baker, Trials 2006 7 30 17022818 10.1186/1745-6215-7-30
29. Survival of patients with nonseminomatous germ cell cancer: a review of the IGCC classification by Cox regression and recursive partitioning. MR van Dijk EW Steyerberg SP Stenning E Dusseldorp JD Habbema, Br J Cancer 2004 90 6 1176 1183 10.1038/sj.bjc.6601665 15026798
30. Survival estimates of a prognostic classification depended more on year of treatment than on imputation of missing values. MR van Dijk EW Steyerberg SP Stenning JD Habbema, J Clin Epidemiol 2006 59 3 246 253 10.1016/j.jclinepi.2005. 08.015 16488355
31. The future of therapy for nonseminomatous germ cell tumors. AC Donadio GJ Bosl, Chest Surg Clin N Am 2002 12 4 769 789 12471877
32. Molecular genetic parameters in pathogenesis and prognosis of testicular germ cell tumors. A Heidenreich S Srivastava JW Moul R Hofmann, Eur Urol 2000 37 2 121 135 10.1159/000020128 10705188
33. Markov models in medical decision making: a practical guide. FA Sonnenberg JR Beck, Med Decis Making 1993 13 4 322 338 10.1177/ 0272989X9301300409 8246705
34. Autologous stem cell transplantation for malignancy: a systematic review of the literature. SJ Simnett LA Stewart J Sweetenham G Morgan PW Johnson, Clin Lab Haematol 2000 22 2 61 72 10.1046/j.1365-2257.2000.00270.x 10792394
35. Phase III trial of conventional-dose chemotherapy alone or with high-dose chemotherapy for metastatic germ cell tumors (GCT) patients (PTS): A cooperative group trial by Memorial Sloan-Kettering Cancer Center, ECOG, SWOG, and CALGB. DF Bajorin CR Nichols KA Margolin J Bacik PG Richardson NJ Vogelzang L Einhorn M Mazumdar GJ Bosl RJ Motzer, J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 4510
36. Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy. M Bower ES Newlands L Holden GJ Rustin RH Begent, Ann Oncol 1997 8 5 477 483 10.1023/A:1008279222625 9233528
37. BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: the Spanish Germ-Cell Cancer Group experience (GG). JR Germa-Lluch X Garcia del Muro JM Tabernero M Sanchez J Aparicio E Alba A Barnadas, Ann Oncol 1999 10 3 289 293 10.1023/A:1008351022211 10355572
38. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. SB Kaye GM Mead S Fossa M Cullen R deWit I Bodrogi C van Groeningen R Sylvester L Collette S Stenning L De Prijck E Lallemand P deMulder, J Clin Oncol 1998 16 2 692 701 9469359
39. Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948). SD Fosså B Paluchowska A Horwich G Kaiser PH de Mulder O Koriakine AT van Oosterom L de Prijck L Collette R de Wit EORTC GU Group, Br J Cancer 2005 93 11 1209 1214 10.1038/sj.bjc.6602830 16251877
40. Phase II/III Randomized Study of Bleomycin, Cisplatin, and Etoposide (BEP) Versus Bleomycin, Cisplatin, Etoposide, and Paclitaxel (T-BEP) in Men With Intermediate Prognosis Germ Cell Cancer. EORTC, http://www.cancer.gov/search/ ViewClinicalTrials.aspx?cdrid=66731&protocolsearchid=1937772&version= healthprofessional
41. Long-term effects on sexual function and fertility after treatment of testicular cancer. JT Hartmann C Albrecht HJ Schmoll MA Kuczyk C Kollmannsberger C Bokemeyer, Br J Cancer 1999 80 5-6 801 807 10.1038/sj.bjc.6690424 10360658